Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Generics Office To Be Managed By Relative Unknown

This article was originally published in The Pink Sheet Daily

Executive Summary

Director Uhl’s medical leave puts bioequivalence office head John Peters in the limelight.

You may also be interested in...



FDA Generic Office Director Uhl Returns From Medical Leave

Kathleen Uhl's five-month leave for cancer treatment ends as user fee negotiations move towards formal start.

GDUFA II Negotiations: Let the Saber-Rattling Begin

The reauthorization of the Generic Drug User Fee Act isn’t going to be as straightforward as the PDUFA process has been for the past two decades. Instead, expect a replay of the first medical device fee renegotiation – with plenty of threats from industry to walk away from the program altogether, likely intended to end up with the best possible deal.

ANDA Approval Whiplash: Strong April Follows Terrible March

Picture still seems pretty grim, but FDA points to progress on several metrics.

Related Content

Topics

UsernamePublicRestriction

Register

PS078330

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel